	US 12,264,356 B2
	Method for determining sensitivity to SGLT2 inhibitor and sensitivity marker for SGLT2 inhibitor
Tadateru Takayama, Tokyo (JP); Masahiro Usui, Miyagi (JP); and Keiko Kudo, Tokyo (JP)
Assigned to NIHON UNIVERSITY, Tokyo (JP); OSAKI CITY, Osaki (JP); and NIPPON KAYAKU KABUSHIKI KAISHA, Tokyo (JP)
Filed by NIHON UNIVERSITY, Tokyo (JP); OSAKI CITY, Osaki (JP); and NIPPON KAYAKU KABUSHIKI KAISHA, Tokyo (JP)
Filed on Feb. 24, 2020, as Appl. No. 16/799,064.
Claims priority of application No. 2019-031366 (JP), filed on Feb. 25, 2019.
Prior Publication US 2020/0347458 A1, Nov. 5, 2020
Int. Cl. C12Q 1/26 (2006.01); C12Q 1/6886 (2018.01)

CPC C12Q 1/26 (2013.01) [C12Q 1/6886 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01); G01N 2800/042 (2013.01); G01N 2800/52 (2013.01)]

14 Claims

1. A method for treating diabetes in a subject, the method comprising the steps of:

measuring a biomarker in a biological sample of the subject to obtain a biomarker value, wherein the subject has not previously taken an SGLT2 inhibitor;

determining that the subject has a measured biomarker value of 5 μg/ml or less, where an HbAlc value of the subject is expected to decrease by 10% or more after administrating the SGLT2 inhibitor; and

administering the SGLT2 inhibitor to the subject, wherein

the biomarker is 1,5-anhydroglucitol, and the biological sample is blood obtained from the subject.